Wave Life Sciences Ltd. (WVE)
| Market Cap | 1.33B +41.7% |
| Revenue (ttm) | 42.73M -60.5% |
| Net Income | -204.38M |
| EPS | -1.21 |
| Shares Out | 192.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,823,175 |
| Open | 7.18 |
| Previous Close | 7.18 |
| Day's Range | 6.87 - 7.37 |
| 52-Week Range | 5.02 - 21.73 |
| Beta | -1.32 |
| Analysts | Strong Buy |
| Price Target | 29.50 (+325.07%) |
| Earnings Date | Apr 28, 2026 |
About WVE
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc... [Read more]
Financial Performance
In 2025, Wave Life Sciences's revenue was $42.73 million, a decrease of -60.55% compared to the previous year's $108.30 million. Losses were -$204.38 million, 110.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price target is $29.5, which is an increase of 325.07% from the latest price.
News
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of ...
Wave Life Sciences Announces Proposed Redomiciliation to the United States
CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences stock crash: why analyst sees a buying opportunity
Wave Life Sciences (NASDAQ: WVE) shares have been cut in half on Thursday, even though the biotechnology company reported Phase 1 data for an obesity drug that management dubbed “positive”. The sudden...
Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?
At the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant placebo-adjusted reductions in visceral fat by 14%, total fat by 5%, and waist circumference by 3%, while stabilizi...
WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave ...
Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints
Wave Life Sciences shares plunged over 55% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a dangerous type of belly fat.
Wave Life Sciences Transcript: Study result
Interim phase I data for WVE-007 in overweight/obese adults showed a 14% reduction in visceral fat and preserved muscle after a single dose, with a strong safety profile and durable Activin E suppression. Phase II/a will target higher BMI populations to demonstrate greater efficacy and inform broader metabolic indications.
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p
FDA reversals leave investors worrying about the fates of other experimental drugs
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co...
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS confere...
Wave Life Sciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The discussion highlighted advances in oligonucleotide and RNA editing therapies, with clinical data showing promising fat loss and muscle preservation in obesity, and robust protein correction in alpha-1 antitrypsin deficiency. Upcoming studies will target higher BMI populations and explore broader indications, supported by scalable manufacturing and innovative modalities.
Wave Life Sciences Earnings Call Transcript: Q4 2025
Revenue and net income declined year-over-year due to the end of the Takeda collaboration, but clinical progress in obesity and AATD programs was strong, with positive interim data and upcoming regulatory milestones. Cash reserves are expected to fund operations into Q3 2028.
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while...
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path
On Monday, Wave Life Sciences Ltd. (NASDAQ: WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE: GSK).
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved t...
Wave Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted rapid advances in RNA medicines, with a focus on innovative siRNA and RNA editing programs for obesity, AATD, and liver disease. Key obesity data show fat loss with muscle preservation, and multiple clinical milestones are expected in 2024.
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-...
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...
Why Did Wave Life Sciences Surge 147%?
A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely wha...
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...
What's Going On With Wave Life Sciences Stock Tuesday?
Wave Life Sciences Ltd. (NASDAQ: WVE) stock rose Tuesday on continued optimism after the company announced data from the lowest therapeutic cohort of the ongoing INLIGHT trial of WVE-007 for weight lo...
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...